ClinicalTrials.gg
CompletedNCT00002371Updated May 4, 2011

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

A Phase 3 interventional study of Indinavir sulfate and Lamivudine in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-04.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
79th of 126
80 · median 154
Started
1996
the only one that year
Phase 3
50 of 132
2 open now
Registered
1st of 132
by date
Lead sponsor
5 of 132
Bristol-Myers Squibb

Among the 132 studies testing lamivudine in HIV Infections, this one is the 79th largest by enrollment of the 126 interventional ones that give a count, is the only one that started in 1996, is one of 50 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

To compare the magnitude and durability of the reduction in plasma HIV RNA in the two treatment groups over the first 12 weeks of treatment. To determine the safety of each of the two treatment groups.

Read the detailed description

Patients will be randomized to either Stavudine (d4T) + Lamivudine (3TC) + Zidovudine placebo or Zidovudine (ZDV) + Lamivudine + Stavudine placebo. Patients whose plasma HIV RNA levels remain >= 500 copies/ml after 8 weeks of blinded double combination therapy will have indinavir added to their treatment regimen at the week 12 visit.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • Stavudine
  • Lamivudine
  • RNA, Viral
  • Anti-HIV Agents
  • Viral Load
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • At least six months of prior cumulative ZDV therapy.
  • Qualifying plasma RNA count of >= 4 log10 copies/ml obtained within 2 weeks of randomization.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

  • Presence of newly diagnosed AIDS defining opportunistic infection requiring acute therapy at time of enrollment.
  • Intractable diarrhea (>= 6 loose stools/day for >= 7 consecutive days).
  • Signs and symptoms of bilateral peripheral neuropathy >= grade 2 at the time of screening.
  • Inability to tolerate oral medication.
  • Any other clinical conditions that in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements.

Concurrent Medication:

Excluded:

  • Therapy with agents with systemic myelosuppressive, neurotoxic pancreatotoxic, hepatotoxic or cytotoxic potential.
  • Therapy with rifampin, rifabutin, terfenadine, astemizole, cisapride, triazolam, midazolam and ketoconazole at any time while on indinavir therapy.

Patients with any of the following prior conditions or symptoms are excluded:

  • History of acute or chronic pancreatitis.
  • Prior history of bilateral peripheral neuropathy.
  • Intractable diarrhea (>= 6 loose stools/day for >= 7 consecutive days) within 30 days prior to study entry.

Prior Medication:

Excluded:

  • Any prior antiretroviral therapy except for ddI, ddC, 3TC or ZDV (for ZDV, as specified in inclusion criteria).
  • Previous therapy with agents with significant systemic myelosuppressive, neurotoxic pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start.
  • Therapy with rifampin, rifabutin, terfenadine, astemizole, cisapride, triazolam, midazolam and ketoconazole within 2 weeks prior to starting indinavir.
  • Any other prior therapy that, in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing regimen.

Risk Behavior:

Excluded:

  • Active alcohol abuse, sufficient in the investigator's opinion, to prevent compliance with study therapy or to increase the risk of developing pancreatitis.

Required:

At least 6 months of prior cumulative ZDV therapy.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
80 participants
06

Study locations

8 sites
  • Harbor UCLA Med Ctr
    Torrance, California 90502, United States
  • Univ of South Florida
    Tampa, Florida 33612, United States
  • SUNY at Stony Brook / Division of Infectious Diseases
    Stony Brook, New York 11794, United States
  • Houston Clinical Research Network / Div of Montrose Clinic
    Houston, Texas 77006, United States
  • Univ of Utah / School of Medicine / Div of Infect Dis
    Salt Lake City, Utah 84132, United States
  • Sunnybrook Health Science Ctr
    North York, Ontario, Canada
  • Montreal Gen Hosp / Div of Clin Immuno and Allergy
    Montreal, Quebec, Canada
  • Univ of Puerto Rico School of Medicine
    San Juan, 00927, Puerto Rico
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1996, a primary completion of Dec 1997 and a completion of Dec 1997. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 1999
First posted
Aug 31, 2001
Start
Jun 1996
Primary completionActual
Dec 1997
CompletionActual
Dec 1997
Results delay requested
Apr 13, 2011
Last update
May 4, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002371
First posted
Aug 31, 2001
Start date
Jun 1996
Primary completion
Dec 1997
Completion
Dec 1997
Last update
May 4, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Stavudine · Zidovudine

Start the discussion